Target intelligence / Profile preview

Tyrosyl-tRNA synthetase 2 (YARS2)

Target
YARS2
Molecular classification
Enzyme, Aminoacyl-tRNA synthetase, Ligase
01

Overview

Tyrosyl-tRNA synthetase 2 (YARS2) is a mitochondrial enzyme responsible for ligating tyrosine to its cognate tRNA (tRNA^Tyr), an essential step in mitochondrial protein synthesis and normal respiratory chain function[2]. As a class I aminoacyl-tRNA synthetase, YARS2 forms homodimers and contains conserved domains for substrate and tRNA recognition[1][2]. Mutations in YARS2 cause mitochondrial syndromes such as myopathy, lactic acidosis, and sideroblastic anemia. While its canonical role is in translation, recent studies of related cytoplasmic forms suggest possible noncanonical roles in cell signaling and actin organization[3]. No specific drugs currently target YARS2, and loss of its function is associated with profound mitochondrial dysfunction and disease.

Other names
Tyrosyl-tRNA synthetase, mitochondrialYARS2TyrRS2
02

Mechanism of action

Enzyme inhibitors or small molecules could disrupt the aminoacylation of mitochondrial tRNA^Tyr, impairing mitochondrial translation and protein synthesis - Potential allosteric or competitive inhibition at the catalytic site

03

Biological functions

Protein synthesisAminoacylation of tRNA with tyrosineMitochondrial translationRegulation of actin dynamics (noncanonical function)
04

Disease associations

Mitochondrial disorders (including myopathy, lactic acidosis, and sideroblastic anemia)Neurodegenerative diseasePotential roles in cancer and other genetic diseases
05

Safety considerations

Inhibiting mitochondrial tyrosyl-tRNA synthetase leads to mitochondrial dysfunction, with systemic toxicity possibleMutations can cause severe, multi-system mitochondrial disease
06

Interacting drugs

No widely approved drugs target YARS2 specifically; antibiotics targeting mitochondrial translation such as chloramphenicol may have indirect action
07

Biomarkers

YARS2 mutation status can serve as a biomarker for specific mitochondrial myopathy syndromesAccumulation of uncharged tRNA^Tyr and biochemical markers of mitochondrial dysfunction

Beyond the preview

Go deeper on Tyrosyl-tRNA synthetase 2 (YARS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tyrosyl-tRNA synthetase 2 (YARS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call